Jan 8 (Reuters) - Syros Pharmaceuticals Inc:
* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES
* ON TRACK TO REPORT CLINICAL DATA ON SY-1425 COMBINATIONS AND SY-1365
* CO HAD ABOUT $81.9 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPT 30, 2017
* EXPECTS TO BE ABLE TO FUND ANTICIPATED OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2019 Source text for Eikon: Further company coverage:
 